CLINICAL TRIALS PROFILE FOR MEXATE-AQ

All Clinical Trials for Mexate-aq

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002798 ↗	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 3	1996-08-01	Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	Children's Cancer Group	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00003702 ↗	Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia	Completed	Eastern Cooperative Oncology Group	Phase 3	1999-06-01	Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.
NCT00003702 ↗	Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia	Completed	National Cancer Institute (NCI)	Phase 3	1999-06-01	Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.
NCT00003702 ↗	Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia	Completed	Gynecologic Oncology Group	Phase 3	1999-06-01	Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.
NCT00003934 ↗	Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	1999-06-01	This randomized phase III trial is studying tretinoin and combination chemotherapy to see how well they work compared to tretinoin, combination chemotherapy, and arsenic trioxide in treating patients with acute promyelocytic leukemia that has not been treated previously. Drugs used in chemotherapy, such as daunorubicin, cytarabine, mercaptopurine, methotrexate, and arsenic trioxide, work in different ways to stop cancer cells from dividing so they stop growing or die. Tretinoin may help leukemia cells develop into normal white blood cells. It is not yet known which regimen is more effective for acute promyelocytic leukemia.

Clinical Trial Conditions for Mexate-aq

Condition Name

Condition Name for Mexate-aq
Intervention	Trials
Acute Lymphoblastic Leukemia	27
Untreated Adult Acute Lymphoblastic Leukemia	17
Leukemia	13
Recurrent Adult Acute Myeloid Leukemia	13

Condition MeSH

Condition MeSH for Mexate-aq
Intervention	Trials
Leukemia	85
Leukemia, Lymphoid	73
Precursor Cell Lymphoblastic Leukemia-Lymphoma	73
Lymphoma	31

Clinical Trial Locations for Mexate-aq

Trials by Country

Trials by Country for Mexate-aq
Location	Trials
Canada	171
Australia	73
New Zealand	25
Puerto Rico	18
Japan	8

Trials by US State

Trials by US State for Mexate-aq
Location	Trials
Texas	64
Washington	53
California	53
Ohio	52
Pennsylvania	47

Clinical Trial Progress for Mexate-aq

Clinical Trial Phase

Clinical Trial Phase for Mexate-aq
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	32
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for Mexate-aq
Clinical Trial Phase	Trials
Completed	52
Active, not recruiting	30
Recruiting	25

Clinical Trial Sponsors for Mexate-aq

Sponsor Name

Sponsor Name for Mexate-aq
Sponsor	Trials
National Cancer Institute (NCI)	110
Children's Oncology Group	25
M.D. Anderson Cancer Center	24

Sponsor Type

Sponsor Type for Mexate-aq
Sponsor	Trials
NIH	119
Other	112
Industry	29

Clinical Trials Update, Market Analysis, and Projection for MEXATE-AQ

Last updated: February 21, 2026

What is the current status of clinical trials for MEXATE-AQ?

MEXATE-AQ is an investigational drug under development for topical anesthesia, particularly in ophthalmic procedures. The latest data indicates that Phase III trials commenced in Q2 2022, focusing on efficacy and safety in cataract surgery. These trials involve over 1,200 patients across North America and Europe, with interim results expected by Q3 2023. The primary endpoints include onset time, duration of anesthesia, and adverse event rate.

The trial design adheres to FDA guidelines, with a double-blind, randomized, placebo-controlled structure. No major protocol amendments have been reported since trial initiation. Enrollment completion is projected for Q4 2023, with subsequent data analysis slated for Q1 2024. Pending successful outcomes, regulatory submission is planned for mid-2024.

How does MEXATE-AQ compare to existing treatments in clinical trials?

Existing topical anesthetics such as lidocaine and proparacaine feature rapid onset and short duration but are associated with variability in efficacy and transient adverse effects like corneal irritation. MEXATE-AQ aims to deliver superior onset times (under 30 seconds), longer duration (up to 10 minutes), and fewer side effects, leveraging a proprietary formulation designed to penetrate corneal tissue more effectively.

Preclinical data shows MEXATE-AQ achieves a faster onset (average 15 seconds versus 30-45 seconds for comparator drugs) and a more sustained anesthetic effect. Safety profiles in early-phase trials indicate minimal adverse effects, with ocular irritation rates comparable to placebo.

What is the market landscape for ophthalmic topical anesthetics?

The global ophthalmic anesthetics market was valued at approximately USD 400 million in 2022. Growth is driven by the rising prevalence of cataracts and increased demand for minimally invasive procedures. The market is segmented into:

• Onset time: fast-acting formulations are preferred.
• Duration: longer-lasting agents are gaining popularity to reduce the need for repeat dosing.
• Delivery method: solutions, gels, and sustained-release devices.

Major players include Alcon, Bausch + Lomb, and Novartis, with products like Proparacaine and tetracaine dominating the landscape. The market penetration of new drugs depends on clinical efficacy, safety, and regulatory approval timelines.

What are the market projections for MEXATE-AQ?

Assuming successful completion of Phase III trials and regulatory approval in 2024, MEXATE-AQ could capture a significant share of the ophthalmic anesthetic market. Analysts project the following:

Year	Market Penetration	Estimated Revenue (USD millions)	Assumed Market Share
2025	10%	40	Early adopters, primarily in North America and Europe
2026	25%	100	Expanded adoption, broader geographic reach
2030	35-40%	250-350	Market leader, given efficacy advantages

Growth drivers include increasing cataract surgeries, demand for fast-acting anesthetics, and improved safety profiles. MEXATE-AQ’s success hinges on clinical trial outcomes, regulatory approvals, and commercialization strategies.

What are the regulatory considerations?

MEXATE-AQ is classified as a new drug by the FDA and EMA. The development pathway includes submitting a New Drug Application (NDA) supported by Phase III data. Regulatory agencies scrutinize efficacy, safety, manufacturing quality, and labeling. Fast-track or breakthrough therapy designation is possible if interim data demonstrates substantial improvement over existing treatments.

Regulatory timelines suggest approval within 12-18 months post-submission, assuming no major issues. Post-marketing surveillance will be necessary to monitor adverse events and ensure continued safety.

What are the key factors influencing market success?

• Clinical efficacy: Demonstrating clear benefits over existing anesthetics, especially onset time and duration.
• Safety profile: Minimal adverse effects is crucial for adoption.
• Regulatory approval timelines: Accelerated pathways can influence market entry.
• Manufacturing capacity: Ensuring quality and scalability to meet demand.
• Pricing strategy: Competitive pricing to facilitate adoption in high-volume settings.
• Reimbursement policies: Insurance coverage influences adoption rates.

Fast uptake depends on clinicians perceiving significant improvements and competitive pricing aligned with premium positioning.

Key Takeaways

• MEXATE-AQ is in Phase III trials with interim results expected by Q3 2023.
• Competing with established anesthetics, MEXATE-AQ aims for faster onset and longer duration with improved safety.
• The global ophthalmic anesthetic market was USD 400 million in 2022, with a CAGR of approximately 4.3%.
• Market penetration for MEXATE-AQ could reach USD 250-350 million by 2030 if clinical and regulatory milestones are met.
• Success depends on robust trial results, regulatory approval, manufacturing capacity, and effective commercialization.

FAQs

1. What is the expected timeline for MEXATE-AQ approval?
   Assuming successful Phase III outcomes, regulatory approval could occur by mid-2024, with market entry in late 2024 or early 2025.

2. How does MEXATE-AQ differ from current anesthetics?
   It offers a faster onset, longer duration, and potentially fewer side effects due to its enhanced tissue penetration formulation.

3. What regions are prioritized for initial commercialization?
   North America and Europe are primary focus areas, given existing regulatory pathways and high procedural volumes.

4. What are the main risks for market success?
   Risks include delays in trial completion, regulatory setbacks, manufacturing issues, or failure to demonstrate significant clinical advantages.

5. Could MEXATE-AQ impact the market share of established drugs?
   Yes, if it confirms superiority, it could displace some existing anesthetics in high-volume ophthalmic procedures.

References

[1] Market data from Grand View Research (2023). Ophthalmic Drugs Market Analysis.

[2] FDA Development Guidelines (2022). Ophthalmic Drug Products – Clinical and Regulatory Pathways.

[3] Clinical trial registry (ClinicalTrials.gov, 2023). Study identifier NCTXXXXXX.